Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan hydrochloride liposome + anlotinib + enlonstobart
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is an investigational regimen consisting of irinotecan hydrochloride liposome, anlotinib, and enlonstobart. **Irinotecan hydrochloride liposome** is a liposomal formulation of the cytotoxic topoisomerase I inhibitor irinotecan, designed to provide sustained drug release and improved tumor penetration. **Anlotinib** is a multi-target small molecule tyrosine kinase inhibitor that primarily targets VEGFR1/2/3, FGFR1-4, PDGFR alpha/beta, and c-Kit, thereby inhibiting tumor angiogenesis and proliferation. **Enlonstobart** (also known as SG001) is a humanized monoclonal antibody that acts as a checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor, enhancing the immune system's anti-tumor response. The combination is being evaluated for its synergistic potential in treating advanced solid tumors, particularly colorectal cancer, by simultaneously attacking the tumor through cytotoxic, anti-angiogenic, and immunotherapeutic pathways.
- Brand names
- Duoenda
- Other names
- SG001 + AL3818 + Irinotecan Liposome
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on irinotecan hydrochloride liposome + anlotinib + enlonstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan hydrochloride liposome + anlotinib + enlonstobart.